Halo Biosciences
Transforming the treatment of
inflammatory and fibrotic disease
Halo Biosciences
Transforming the treatment of
inflammatory and fibrotic disease
Our Mission
Halo is a clinical-stage biotechnology company creating first-in-class, disease-modifying therapies for inflammatory and fibrotic disease. Our first focus is pulmonary hypertension and interstitial lung disease.
Our Science
The ECM in Disease
We are building a differentiated pipeline based on novel insights into how dysregulation of the extracellular matrix (ECM) drives disease
Our primary target is Hyaluronan (HA), a key component of the ECM
Alterations to HA and to the ECM have strong associations with a variety of conditions characterized by inflammation and fibrosis, including pulmonary hypertension, pulmonary fibrosis, and liver fibrosis
Our Pipeline
Novel target for inflammation and fibrosis
Our pipeline is focused on delivering first-in-class and best-in-class hyaluronan remodeling agents, acting on novel targets with a differentiated mechanism of action
Our lead indications are pulmonary hypertension and interstitial lung disease, progressive and fatal diseases characterized by inflammation, fibrosis, and vascular remodeling of the lung